Advertisement

Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review

      Highlights

      • Chronic immunosuppression is crucial in preventing NMSOD relapses.
      • CD27+ B cells might be a useful biomarker to guide RTX retreatment in AQP4-IgG positive patients.
      • Relapses in anti-MOG NMSOD occurred regardless of B cell depletion.

      Abstract

      Introduction

      Several studies have shown the efficacy of rituximab (RTX) in preventing relapses in patients suffering from Neuromyelitis Optica spectrum disorder (NMSOD) and have explored different therapeutic schemes. Given the extreme inter-individual variability of the disease course, there is the need to identify biomarkers to tailor the retreatment schedule and dosage. This review aimed to identify the most useful biomarker to guide reinfusion and, in turn, the optimal retreatment schedule of RTX for NMSOD.

      Methods

      The literature search was conducted in the Web of Science, Scopus and Pubmed electronic databases. We limited document type to articles written in English and published up to 28 February 2022. Inclusion criteria were: (i) Patients affected by NMSOD and treated with RTX, (ii) followed up for at least one year and for whom Annualized Relapse rate (ARR) was collected over a period of at least 12 months before and after therapy initiation and (iii) induction protocols consisting of 375 mg / m2 / week for four weeks or 1000 mg infused once or twice two weeks apart. Collected information was: first authors' name, publication year, study design, sample size, sex, age, percentage of patients positive for antibodies to aquaporin 4 (AQP4-IgG), maintenance regimen, primary outcome, mean ARR pre-therapy and mean ARR post-therapy initiation, percentage of relapse-free patients. The primary outcome that we considered was the ARR reduction. Further, we considered the number of relapses that occurred when B cells and memory B cells were under the chosen threshold and the percentage of relapse-free patients when available.

      Results

      Among 31 potentially eligible studies, 9 fulfilled the inclusion criteria. ARR reduction was not comparable between studies. The studies that monitored CD19+ and CD27+ cell kinetics showed a higher number of relapses when CD19+ lymphocyte count was below the threshold compared to the number of relapses that occurred when CD27+ cell count was below the threshold. Further, a higher percentage of patients achieved the relapse-free condition with a reinfusion schedule when CD27+ reached 0, 05% of peripheral blood mononuclear cells (PBMCs) compared to the reinfusion when CD19+ reached 0, 1% of PBMCs.

      Conclusions

      To date, the optimal retreatment schedule for RTX in NMOSD has not yet been determined. However, the presented findings suggest that CD27+ B cells might be a reliable biomarker to guide retreatment in AQP4-IgG positive patients, at least in the first six months from the infusion. Further effort is needed to identify those factors influencing anti-CD20 therapy effectiveness to tailor dosage and treatment schedule to achieve the most favourable risk/benefit ratio.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aktas O.
        • et al.
        Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker.
        Ann. Neurol. 2021; 89: 895-910https://doi.org/10.1002/ana.26067
        • Annovazzi P.
        • et al.
        Rituximab in the treatment of Neuromyelitis Optica: a multicentre Italian observational study.
        J. Neurol. 2016; 263: 1727-1735https://doi.org/10.1007/s00415-016-8188-y
        • Bennett J.L.
        • et al.
        B lymphocytes in neuromyelitis optica.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e104https://doi.org/10.1212/NXI.0000000000000104
        • Cabre P.
        • et al.
        Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
        J. Neurol. 2018; 265: 917-925https://doi.org/10.1007/s00415-018-8771-5
        • Capobianco M.
        • et al.
        Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
        Neurol. Sci. 2007; 28: 209-211https://doi.org/10.1007/s10072-007-0823-z
        • Carroll W.M.
        • et al.
        Neuromyelitis optica.
        Curr. Treat. Options. Neurol. 2010; 12 (May): 244-255https://doi.org/10.1007/s11940-010-0071-z
        • Casallas-Vanegas A.
        • et al.
        Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
        J. Neurol. Sci. 2020; 419 (15)117204https://doi.org/10.1002/ana.25648
        • Cohen M.
        • et al.
        Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study.
        J. Neurol. Sci. 2017; 373: 335-338https://doi.org/10.1016/j.jns.2017.01.025
        • Collongues N.
        • et al.
        Efficacy of rituximab in refractory neuromyelitis optica.
        Mult. Scler. 2015; 22: 955-959https://doi.org/10.1177/1352458515602337
        • Cree B.A.
        • et al.
        An open label study of the effects of rituximab in neuromyelitis optica.
        Neurology. 2005; 64: 1270-1272https://doi.org/10.1212/01.WNL.0000159399.81861.D5
        • Damato V.
        • et al.
        Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta- analysis.
        JAMA Neurol. 2016; 73: 1342-1348https://doi.org/10.1001/jamaneurol.2016.1637
        • Durozard P.
        • et al.
        Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases.
        Ann. Neurol. 2020; 87 (2020 Feb): 256-266https://doi.org/10.1002/ana.25648
        • Evangelopoulos ME
        • et al.
        Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
        J. Neurol. Sci. 2017; 372 (15): 92-96https://doi.org/10.1016/j.jns.2016.11.016
        • Hyun JW.
        • et al.
        Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein.
        Neurol. Neuroimmunol. Neuroinflamm. 2021; 8 (9): e965https://doi.org/10.1212/NXI.0000000000000965
        • Ip VH.
        • et al.
        Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.
        J. Neurol. Sci. 2013; 324 (15): 38-39https://doi.org/10.1016/j.jns.2012.09.024
        • Jacob A.
        • et al.
        Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
        Arch. Neurol. 2008; 65: 1443-1448https://doi.org/10.1001/archneur.65.11.noc80069
        • Jarius S.
        • et al.
        Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients.
        J. Neuroinflammation. 2012; 9: 14https://doi.org/10.1186/1742-2094-9-14
        • Jarius S.
        • et al.
        Neuromyelitis optica.
        Nat. Rev. Dis. Primers. 2020; 6: 85https://doi.org/10.1038/s41572-020-0214-9
        • Jarius S.
        • Wildemann B.
        Devic's index case: a critical reappraisal – AQP4-IgG- mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?.
        J. Neurol. Sci. 2019; 407116396https://doi.org/10.1016/j.jns.2019.07.014
        • Kim S.H.
        • et al.
        Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
        Arch. Neurol. 2011; 68: 1412-1420https://doi.org/10.1001/archneurol.2011.154
        • Kim S.H.
        • et al.
        A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
        JAMA Neurol. 2013; 70: 1110-1117https://doi.org/10.1001/jamaneurol.2013.3071
        • Kim S.H.
        • et al.
        Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab.
        JAMA Neurol. 2015; 72: 989-995https://doi.org/10.1001/jamaneurol.2015.1276
        • Kim S.H.
        • et al.
        Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
        Neurochem. Int. 2019; 130104347https://doi.org/10.1016/j.neuint.2018.11.022
        • Kim SH.
        Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies.
        Neurol. Neuroimmunol. Neuroinflamm. 2021; 8 (23): e947https://doi.org/10.1212/NXI.0000000000000947
        • Lebrun C.
        • et al.
        Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders.
        Neurol. Ther. 2018; 7373383https://doi.org/10.1007/s40120-018-0101-4
        • Lennon V.A.
        • et al.
        A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
        Lancet. 2004; 364: 2106-2112https://doi.org/10.1016/S0140-6736(04)17551-X
        • Lindsey J.W.
        • et al.
        Variable results after rituximab in neuromyelitis optica.
        J. Neurol. Sci. 2012; 317: 103-105https://doi.org/10.1016/j.jns.2012.02.017
        • Marignier R.
        • et al.
        Myelin-oligodendrocyte glycoprotein antibody-associated disease.
        Lancet Neurol. 2021; 20: 762-772https://doi.org/10.1016/S1474-4422(21)00218-0
        • Moher D.
        • et al.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6 (21)e1000097https://doi.org/10.1371/journal.pmed.1000097
        • Novi G.
        • et al.
        Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
        Mult. Scler. Relat. Disord. 2019; 36101430https://doi.org/10.1016/j.msard.2019.101430
        • Radaelli M.
        • et al.
        Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
        Mult. Scler. 2016; 22: 511-519https://doi.org/10.1177/1352458515594042
        • Whittam DH.
        • et al.
        Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.
        Mult. Scler. Relat. Disord. 2020; 44102251https://doi.org/10.1016/j.msard.2020.102251
        • Yang CS.
        • et al.
        Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.
        Neurology. 2013; 81 (20): 710-713https://doi.org/10.1212/WNL.0b013e3182a1aac7
        • Zhao S.
        • et al.
        Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis.
        Front. Neurol. 2021; 12637932https://doi.org/10.3389/fneur.2021.637932